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Summary
Objective: To investigate whether early changes in biochemical markers of bone (NTX-I) and cartilage (CTX-II [C-terminal crosslinking telo-
peptide of type II collagen]) degradation are associated with radiological progression in patients with knee osteoarthritis (OA) receiving
risedronate.
Design: Two thousand four hundred and eighty three patients with medial compartment knee OA were randomized in two 24-month studies in
North America (NA) and European Union (EU). Studies evaluated risedronate 5 mg/day, 35 mg/week (EU), 50 mg/week (NA), and 15 mg/day
(NA and EU), compared to placebo in reducing signs and symptoms and in slowing radiographic progression. One thousand eight hundred
and eighty ﬁve patients from the pooled EU and NA studies with available NTX-I/CTX-II at both baseline and 6 months and radiographs at
baseline and at 24 months were analyzed.
Results: Risedronate produced a dose-dependent reduction of NTX-I and CTX-II observed at 6 months which continued up to 24 months.
Patients who had CTX-II levels returned to low levels (<150 ng/mmol creatinine) at 6 months had a lower risk of radiographic progression
at 24 months than patients whose CTX-II levels were increased both at baseline and 6 months [odds-ratio (95% conﬁdence interval): 0.57
(0.39e0.85) after adjustment for demographics and joint space width]. The lowest risk of progression was observed in patients who had
low CTX-II levels both at baseline and at 6 months [odds-ratio 0.36 (0.21e0.63)]. No signiﬁcant association between NTX-I levels and radio-
logical progression was observed.
Conclusion: CTX-II decreased with risedronate in patients with knee OA and levels reached after 6 months were associated with radiological
progression at 24 months. Monitoring a marker of cartilage degradation 6 months after initiating treatment may be instructive in identifying
patients with low progression.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a prevalent disease that particularly
affects weight-bearing joints such as knees and hips1. Cur-
rent therapies for OA are mainly targeted toward providing
symptom relief2, and only a few studies have reported efﬁ-
cacy of drugs on modifying disease progression including1This manuscript was sponsored by a grant from Procter &
Gamble.
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660preservation of radiological joint structure3e6. Although the
major structural feature of OA is cartilage degeneration,
OA is also characterized by osteophyte formation, synovial
activation, and subchondral bone abnormalities.
The participation of subchondral bone alterations in the
pathogenesis of OA has initially been suggested by bone
scan studies showing that increased tracer uptake is asso-
ciated with increased risk of radiographic progression in OA
of the knee7. The role of subchondral bone abnormalities as
a major factor in disease progression has also been sup-
ported by the use of magnetic resonance imaging (MRI)
and biochemical markers of bone turnover8e10. Conse-
quently, modulating subchondral bone turnover by anti-
resorptive agents such as bisphosphonates has become
an attractive approach as a potential structure modifying
anti-OA drug (SMOAD) target.
661Osteoarthritis and Cartilage Vol. 16, No. 6Although joint space narrowing (JSN) measured using
plain radiography is the primary measure to assess struc-
tural progression currently accepted by regulatory agencies
in pivotal clinical trials, soluble biochemical markers may be
more sensitive in detecting short term changes because
they reﬂect dynamic biological variation11. Several markers
have been described which differ by tissue speciﬁcity and
sensitivity in detecting alterations in OA11,12. Among these,
a single measurement of urinary cross-linked C-telopepti-
des of type II collagen (CTX-II [C-terminal crosslinking telo-
peptide of type II collagen]), a marker of cartilage
degradation, has been associated with radiological progres-
sion in patients with knee and hip OA13e15. Retrospective
analyses of clinical trials in postmenopausal women have
shown that the bisphosphonates alendronate, ibandronate
and risedronate administered at approved doses for
osteoporosis induced a signiﬁcant decrease of CTX-II16.
A dose-dependent reduction of CTX-II was also seen with
risedronate given at 5 mg/day and 15 mg/day in a 1 year
placebo-controlled study of patients with knee OA17. We
reported earlier that risedronate did not decrease symptoms
or radiological progression compared to placebo over 24
months in two randomized phase III trails18. We now present
further analysis of data in that study on bone and cartilage
markers and their association to radiological progression.Patients and methodsSTUDY DESIGN AND SELECTION OF PATIENTSTwo parallel 24-month double-blind placebo-controlled, multicenter
European (EU) and North America (NA) studies were conducted. A detailed
description of these studies has recently been published18. Brieﬂy, male and
female subjects between 40 and 80 years of age and fulﬁlling the American
College of Rheumatology19 criteria for symptomatic primary knee OA were
recruited.
Clinical inclusion criteria were the presence of signal knee pain due to OA
on most days during at least 1 month in a 3-month period prior to screening
plus at least one of the following: age> 50 years, morning knee stiffness last-
ing <30 min or knee crepitus. All patients then underwent radiography of the
knee to conﬁrm the presence of OA using standardized ﬂuoroscopically po-
sitioned semiﬂexed anterioposterior (AP) views as previously described20.
The radiographic inclusion criteria were a joint space width (JSW) between
2 and 4 mm inclusive in the medial knee tibiofemoral compartment and the
presence of at least one osteophyte in the medial or lateral compartments
of the tibiofemoral joint. Patients with concomitant presence of lateral JSN
could be included in the study, but the medial tibiofemoral compartment
has to be narrower than the lateral. If both knees qualiﬁed, the signal knee
was deﬁned as the knee with smaller JSW. Major exclusion criteria were
secondary OA, use of intra-articular hyaluronic acid in the signal knee,
knee injury or diagnostic arthroscopy of the signal knee in the 6 months prior
to enrollment, history of knee surgery in the signal knee at any time, intra-
articular corticosteroids in the 3 months preceding enrollment, non-OA
causes of knee pain in the signal knee such as anserine bursitis, ﬁbromyal-
gia and osteonecrosis, and use of bisphosphonates within 12 months prior to
enrollment.
Patients gave written, informed consent. The study was conducted ac-
cording to the International Conference on Harmonization (ICH) guidelines
for Good Clinical Practice (GCP), and approved by local ethical committees.
It was conducted before the requirement for registration on clinicaltrials.gov.TREATMENT ASSIGNMENTThe EU study included 1255 patients to receive oral risedronate (5 mg/
day, 15 mg/day or 35 mg/week) or placebo. The NA trial included 1242
patients to receive oral risedronate (5 mg/day, 15 mg/day or 50 mg/week)
or placebo. Patients were instructed to take their study medication with at
least 120 mL of water, 30 min before breakfast, or, if the medication was
taken later in the day, at least 2 h prior to or following food ingestion and
at least 30 min before bedtime.STRUCTURE OUTCOME MEASURESThe signal knee JSW was evaluated at baseline, 1 and 2 years at the nar-
rowest point in the medial tibiofemoral compartment using standardized APradiographs, aided by ﬂuoroscopy, and by attaching a metal sphere to the
ﬁbula head to correct magniﬁcation effects according to the procedure of
Buckland-Wright20,21. Each knee was ﬂexed until the tibial plateau was
horizontal relative to the ﬂoor, parallel to the central X-ray beam and perpen-
dicular to the X-ray ﬁlm. The center of the joint, deﬁned by the joint space,
was aligned with the center of the X-ray beam with the aid of the tube’s po-
sitioning light. The precise knee position was obtained visually with the aid of
ﬂuoroscopy. With the heel ﬁxed, the foot was internally or externally rotated
until the tibial spines appeared centrally placed relative to the femoral notch;
then the knee was ﬂexed to achieve superimposition (1 mm) of the anterior
and posterior margins of the medial tibial plateau. Minimum medial compart-
ment JSW was measured with a semi-automated computerized method. The
test/re-test standard deviation (SD) of the difference between radiographs
taken 2 days apart was approximately 0.2 mm based upon repeated mea-
surements in 199 subjects21. Based on this reproducibility data, clinically
meaningful disease progression was deﬁned a priori as a JSN of 0.6 mm
from baseline which corresponded to approximately three times the SD of
the X-ray measurement method for joint space.MARKERS OF BONE AND CARTILAGE RESORPTIONEarly morning fasting urine samples were collected at baseline, months 6,
12 and 24 for measurement of urinary N-terminal crosslinking telopeptide of
type I collagen (NTX-I, Osteomark; OrthoClinical Diagnostics, Rochester,
NY)22 e a marker of bone resorption e and urinary CTX-II (Cartilaps, Nordic
Bioscience, Herlev, Denmark)23. Intra- and inter-assay coefﬁcients of varia-
tion were lower than 10% for both markers. Urinary NTX-I and CTX-II were
corrected for urinary creatinine concentration measured by a standard color-
imetric assay.STATISTICAL ANALYSISThe analysis was performed on all randomized patients who received at
least one dose of study medication and who had baseline and 6 months
marker data available. All statistical analyses were performed using a two-
sided test with a type I error rate of 0.05. This post hoc analysis was based
on the relationships between baseline and 6-month levels of biochemical
markers and radiological progression at 24 months, data that were available
on a total of 1885 patients for the pooled EU and NA studies. We also ana-
lyzed percent changes of NTX-I and CTX-II at 12 and 24 months on a total of
1825 and 1920 patients, respectively. Distribution free conﬁdence limits for
the medians were constructed based on the methods described by Hahn
and Meeker24. Signiﬁcance of percent changes from baseline and placebo
in NTX-I and CTX-II was assessed by analysis of variance (ANOVA).
We constructed a logistic regression model including all known predictors
of progression measured in this cohort. Baseline predictors included body
mass index (BMI), gender, Western Ontario McMaster Universities Osteo-
arthritis Index (WOMAC) pain score, presence/absence of hip OA, knee
crepitus and JSW. Additionally, levels of NTX-I or CTX-II at baseline and
changes at 6 months were added into the model as a continuous variable.
We also entered baseline and 6-month levels of CTX-II as a categorical vari-
able (high vs low, see Table II). Two cut-off values of CTX-II to differentiate
high vs low cartilage turnover were used: (1) the mean level of healthy indi-
viduals with no symptomatic OA25,26. This cut-off was previously used and
shown to be associated with radiological progression in patients with rheu-
matoid arthritis (RA) treated with a disease modifying therapy27 and (2) the
optimal values at baseline and at 6 months to discriminate radiological pro-
gressors and non-progressors at 24 months identiﬁed by receiver operating
curve (ROC) analysis. These values of 297 and 224 ng/mmol creatinine at
baseline and at 6 months, respectively, are close to the cut-point of
251 ng/mmol creatinine identiﬁed previously to be associated with increased
risk of radiological knee OA progression in the largest epidemiological cohort
that has investigated CTX-II14.ResultsPATIENTSThe total numbers of patients in the intention to treat (ITT)
population were 1251 and 1232 for the EU and NA studies,
respectively18. European subjects were 3 years older than
North Americans (mean SE: 63.6 0.23 years vs
60.5 0.25 years, P< 0.0001) and a larger proportion of
them were female (79 vs 61%, P< 0.0001). A larger propor-
tion of NA postmenopausal women was on hormone re-
placement therapy (44 vs 12%, P< 0.0001). The WOMAC
total score and subscales were higher in European com-
pared to North American patients (mean SE total
662 P. Garnero et al.: CTX-II with risedronate in knee OAWOMAC score: 45.8 0.59 vs 40.2 0.65, P< 0.0001).
BMI was slightly higher (P< 0.0001) in NA patients than
in EU patients (meanSE: 30.3 0.14 vs 29.4 0.12),
whereas the minimum JSW was not different (meanSE:
2.971 0.017 vs 2.973 0.017 mm for EU and NA popula-
tions, respectively, P¼ 0.94). Consistent with the higher
age and the larger proportion of postmenopausal women,
the mean values of NTX-I (mean SE: 48.1 0.77 vs
37.5 0.66 nmol/mmol creatinine, P< 0.001 in EU and
NA studies respectively) and CTX-II (366.6 7.1 vs
284.9 6.7 ng/mmol creatinine, P< 0.001) were also
higher in the EU than in the NA patients. As previously
shown18, in both studies, the different treatment groups
were well balanced for demographics, WOMAC scores,
JSW and NTX-I and CTX-II levels.
Table I shows the baseline characteristics of the 1885
patients (out of the total 2483 subjects from the pooled
EU and NA studies) included in this analysis who had
data available for baseline and 6-month levels of NTX-I/
CTX-II and radiological progression at 24 months and the
other 598 patients. Age, BMI and baseline minimum JSW
were very similar and not statistically signiﬁcant different
between the two groups. The proportion of patients with
knee crepitus and concomitant hip OA was also similar
(NS). There was a larger proportion of female patients
among subjects included in this analysis (72 vs 65%,
P¼ 0.0024) and the WOMAC pain score was slightly lower
(P¼ 0.0019) (Table I).EFFECTS OF RISEDRONATE ON MARKERS OF BONE
AND CARTILAGE DEGRADATIONRisedronate induced a dose-dependent decrease of NTX-
I and CTX-II [Fig. 1(A) and (B)]. In both EU and NA studies,
the decrease of CTX-II already reached a plateau after 6
months of treatment which was sustained over 24 months.
In the EU study, at 6 months, 5 mg/day risedronate de-
creased CTX-II by 16.2 2.8 (median: 25.9%) relative
to baseline (P< 0.05 vs baseline and placebo). The de-
crease of CTX-II observed with the equivalent weekly dose
of 35 mg/week was of similar magnitude to the 5 mg/day
dose [Fig. 1(A)]. The largest dose of 15 mg/day produced
the greatest decreases of CTX-II, reaching a meanSE
of 36.9 3.0 (median: 49.5%) at 6 months [Fig. 1(A)].
Results observed in the NA study were similar, both in terms
of pattern and magnitude of changes for equivalent doses to
those of the EU trial [Fig. 1(B)].Table I
Baseline demographics of patients included in the current analysis
and the other patients
Parameter Patients in the
study* (N¼ 1885)
Other patients
(N¼ 598)
Age (years) 62.0 8.56 62.2 9.17
Female gender, n (%) 1357 (72%) 391 (65%)
BMI (kg/m2) 29.9 4.58 29.8 4.41
WOMAC pain score 39.1 21.92 42.3 21.65
Minimum JSW (mm) 3.0 0.60 2.9 0.57
Patients with knee
crepitus, n (%)
1559 (83%) 500 (84%)
Patients with OA
at the hip, n (%)
329 (17%) 92 (15%)
All data are shown as meanSD for quantitative variable.
*Patients with available baseline and 6-month NTX-I/CTX-II data
and 24-month radiological progression.RELATIONSHIPS BETWEEN BIOCHEMICAL MARKERS
AND RADIOGRAPHIC PROGRESSIONBecause there was no statistical difference in radio-
graphic progression analyzed either in continuous or dichot-
omous variables (joint space loss greater or lower than
0.6 mm) between treatment groups or between the EU
and NA cohorts18, the three risedronate treatment arms
from NA and EU were combined with placebo for these
analyses.
As previously reported18, overall 13% of patients had ra-
diographic progression as deﬁned as a joint space
loss 0.6 mm (Table II). When entered in a logistic regres-
sion model as a continuous variable, we found that both
baseline CTX-II levels (P¼ 0.0003) and the absolute
(P¼ 0.0049) or the percent (P¼ 0.0063) change of CTX-II
at 6 months from baseline were signiﬁcantly associated
with 24 months radiological progression after adjusting for
BMI, gender, WOMAC pain, presence of hip OA, knee crep-
itus, treatment and baseline JSW for all analyses and base-
line CTX-II for the change and percent change analyses.
Table II shows the mean radiological joint space loss, the
percentage of patients with radiographic progression at 24
months and the relative risk of progression, stratiﬁed for
baseline and 6 months levels of CTX-II (high vs low). Pa-
tients with low levels of CTX-II both at baseline and at 6
months had a lower radiological joint space loss and a lower
proportion of them demonstrated a signiﬁcant radiological
progression (JSN 0.6 mm) after 24 months than patients
who started the study with increased CTX-II level and in
whom values remained high after 6 months. Patients who
started with high CTX-II levels at baseline who returned to
low levels at 6 months had also a signiﬁcantly lower risk
of progression than patients with sustained high CTX-II
values, although the actual proportion of progressors in
the two groups was similar (11 vs 15%) (Table II). When
the cut-off values based on ROC were used to deﬁne
high and low CTX-II, similar results were obtained (data
not shown). We found no signiﬁcant association between
NTX-I levels at baseline and 6 months when entered in
the logistical model as a continuous or as a categorical
variables and radiological progression at 24 months (data
not shown).
At baseline, 81% of all patients had high CTX-II values
(>150 ng/mmol creatinine). After 6 months, this proportion
remains similar in patients receiving placebo (83%), but
dose-dependently decreased with increasing doses of rise-
dronate (Fig. 2). Even with the highest dose of risedronate
(15 mg/day), still 50% of patients had CTX-II> 150 ng/
mmol after 6 months of treatment. Overall 68% of patients
had CTX-II values> 150 ng/mmol after 6 months of
treatment.Discussion
In this study we report that daily or weekly oral risedro-
nate produced a dose-dependent decrease of urinary
NTX-I and CTX-II which was observed as early as 6 months
after initiating risedronate and which was maintained
through the 24 months treatment period. More importantly,
the baseline and 6 months levels of CTX-II were associated
with radiological progression at 24 months, independently
of clinical and radiological risk factors. This suggests
that the measurement of CTX-II at baseline and after 6
months of follow-up in combination with other known risk
factors may be useful to predict disease progression in
knee OA.
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Fig. 1. Changes of NTX-I and CTX-II in patients with knee OA treated with placebo or risedronate. The graphs show the median and the
conﬁdence interval limits of the percentage change from baseline of NTX-I (left) and CTX-II (right) in the European (A) or North American
(B) study.
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agreement with the previously reported effects of different
bisphosphonates in postmenopausal women with osteopo-
rosis16. The assay for CTX-II uses a monoclonal antibody
directed against a type II collagen C-telopeptide sequence
which is common to various animal species, but speciﬁc
for type II collagen23. In vitro animal and human models
of cartilage and bone explants have shown that CTX-II is
released during degradation of articular cartilage and not
of bone matrix23,28. In patients with Paget’s disease of
bone who are characterized by a marked increased of
bone resorption, urinary CTX-II is not elevated compared
to healthy controls29.
Immuno-histochemistry of cartilage from ovariectomized
rats30 and patients with knee OA31 indicates that CTX-II epi-
tope is not only released at the surface of the cartilage, but
also at the bone to cartilage interface region within theTable I
CTX-II at baseline and 6 months for predicti
CTX-II levels
(baseline/6 months*)
Mean S.E.M. of change in JSW at 24 m
Absolute change (mm) % change from
High/high (n¼ 1152) 0.121 0.015 4.2
High/low (n¼ 372) 0.088 0.023 2.9
Low/high (n¼ 120) 0.108 0.039 4.5
Low/low (n¼ 241) 0.041 0.024 1.6
*Baseline and 6 month cut-off value of CTX-II at 150 nmol/mmol creat
yProgression was deﬁned as a JSN 0.6 mm at any post baseline vis
zRelative risks were adjusted for BMI, gender, WOMAC pain, hip OA,calciﬁed region which is likely to be preferentially altered
by bone anti-catabolic drugs. The decrease of CTX-II we
observed with risedronate may thus in part result from indi-
rect effects of the drug on subchondral bone turnover.
Pre-clinical studies have shown that risedronate preserves
subchondral bone micro-architecture32. More recently using
fractal analysis of knee radiographs in a subgroup of pa-
tients with knee OA included in the current study, it was
shown that the doses of 15 mg/day and 50 mg/week of
risedronate, but not the lower dose of 5 mg/day, maintain
the structural integrity of the cancellous bone of the medial
compartment of the proximal tibia33. By regulating osteo-
clast activity, risedronate could also reduce the secretion
of yet to be identiﬁed pro-catabolic factors which could
increase cartilage degradation.
A direct effect of risedronate on cartilage metabolism
could also be possible. A single intravenous injection ofI
ng 24-month radiographic progression
onths Radiographic progressiony at 24 months
baseline Progressor (%) Relative risk (95% CI)z
0.5 15 1.0 (reference)
0.8 11 0.57 (0.39e0.85)
1.5 13 0.77 (0.43e1.36)
0.9 6 0.36 (0.21e0.63)
inine to separate low and high levels.
it.
knee crepitus at baseline, baseline JSW and treatment allocation.
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Fig. 2. Cartilage turnover classiﬁcation at baseline and at 6 months. The bars show the percentage of patients with knee OA with high and low
urinary CTX-II levels at baseline and after 6 months of treatment with placebo or different doses of risedronate. Patients were categorized as
low (<150 ng/mmol creatinine; white) or high (150 ng/mmol creatinine; black) levels of urinary CTX-II.
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nary CTX-II in patients with Paget’s disease in contrast to
the sustained inhibition of bone resorption as measured
by urinary NTX-I29. It has been reported that alendronate,
inhibits in vitro the activity of matrix-metalloprotease 13
(MMP-13) which is one of the key enzymes involved in car-
tilage degradation in OA34 and in the release of CTX-II frag-
ments from cartilage28,30 (unpublished observations). In
addition to its direct inhibitory effect on enzyme activity, bi-
sphosphonate could also reduce the secretion of MMPs35.
In summary, the rapid decrease of urinary CTX-II following
risedronate may result from a direct and/or indirect effect of
that bisphosphonate on articular and/or calciﬁed cartilage
degradation. We can also not exclude the possibility that
bone matrix contains very small amounts of type II collagen
and thus that inhibition of skeletal turnover by risedronate
could contribute to decreased urinary CTX-II levels.
We explored whether monitoring levels of biochemical
markers during the course of the study could predict radio-
logical progression over 24 months. For NTX-I, we found
no signiﬁcant predictive value of either baseline or 6-month
levels, conﬁrming previous studies in non-bisphosphonate
treated patients indicating that bone turnover markers are
poorly predictive of radiological progression in OA11,15. In
contrast, we found associations between 6-month levels of
CTX-II and 24-month radiological progression, these associ-
ations being signiﬁcant after adjustment for the other clinical
and radiological variables shown to be associated with pro-
gression. The value of baseline CTX-II level to predict radio-
logical progression has been reported in patients with knee
or hip OA who were not taking bisphosphonates13e15. Our
study is, however, the ﬁrst one demonstrating a relationship
between radiological progression and longitudinal changes
of CTX-II after 6 months in patients receiving risedronate.
When entered as a continuous variable we found that both
baseline levels and changes (absolute change or percent-
age change) from baseline at 6 months of CTX-II were asso-
ciated with radiological progression. In further analyses,
however, we have focused on the absolute levels of CTX-II
at 6 months as a predictor of radiological progression and
not the change from baseline both for biological and statisti-
cal principles. Indeed, a treatment whose aim is to prevent
joint damage should bring the level of markers reﬂecting
that process to the one of healthy non-arthritis individuals,independent of pre-treatment levels. This strategy has
been recently applied to bone markers to predict the efﬁcacy
of bisphosphonates on fracture risk in osteoporosis36 or
skeletal related events in patients with cancer and bone
metastases37. From a statistical standpoint, the use of a pa-
rameter (change from baseline) that uses two estimates of
cartilage degradation in its calculation, each with its own var-
iability is likely to be less likely to allow evaluation of a rela-
tionship. We thus dichotomized patients in low and high
CTX-II levels at baseline and at 6 months using the mean
levels of healthy non-arthritis individuals which have previ-
ously used to predict radiological progression in patients
with RA27. We found that patients who started with low
CTX-II levels and who remained at low levels after 6 months
of treatment had a lower risk of progression than those who
had high values at both time points. These data suggest that
the maintenance of low CTX-II levels over 6 months may be
an important factor to identify patients who are relatively pro-
tected from long-term radiological progression in knee OA.
Indeed among these patients only 6% demonstrated a loss
of JSW 0.6 mm after 24 months. Although risedronate
treatment resulted in low CTX-II levels to a larger proportion
than in patients receiving placebo, less than 30% of patients
receiving the lowest doses of 5 mg/day and 35 mg/week had
low values 6 months after initiating treatment. In the highest
dose groups of 50 mg/week and 15 mg/day e which were
the only regimens that had a signiﬁcant effect on subchon-
dral bone turnover33 e this proportion increased but re-
mained below or equal to 50%. This together with the
limited progression observed in this study compared for ex-
ample to the recent doxycycline trial6 may explain the lack
of apparent radiological effects of risedronate in that study,
despite a signiﬁcant, but probably insufﬁcient, reduction of
CTX-II. The validity of the CTX-II cut-off values used in that
study to predict radiological progression will have, however,
to be conﬁrmed in other prospective studies of patients with
knee OA.
Our study has certain strengths and some limitations.
This is the largest study measuring bone and cartilage
markers in a randomized controlled trial with any therapy
in OA. Progression was assessed by a highly standardized
radiographic technique using ﬂuoroscopically positioned
ﬂexed knee view. Our study also has some limitations. As
previously reported in this population18, only a small
665Osteoarthritis and Cartilage Vol. 16, No. 6proportion of patients demonstrated signiﬁcant radiological
progression and contributes to the mean change of JSW.
It was designed as a randomized trial to test the efﬁcacy
of risedronate on radiological progression, not to test the
predictive value of CTX-II. We did not assess knee align-
ment and thus could not conduct an analysis of this param-
eter. We did not evaluate the status of other potential
sources of CTX-II in the body, such as the hips, hands,
spine which contribute to urinary levels of that marker26.
We also did not measure other potentially useful biochemi-
cal markers of OA progression including the type II collagen
degradation markers C2C, C12C38, Helix-II39 and Coll2-140,
the type II collagen synthesis markers; C-terminal propep-
tide of type II procollagen (PIICP)-38 and N-terminal propep-
tide of type IIA procollagen (PIIANP)-13, cartilage oligomeric
matrix protein41 and hyaluronic acid14. However, urinary
CTX-II has been shown to be associated with radiological
OA progression in several prospective studies and it is cur-
rently the only systemic cartilage biochemical marker shown
to decrease with bisphosphonates therapy.Conclusion
This study has shown that measurements of urinary CTX-
II prior to initiating treatment with risedronate and 6 months
after the start of therapy provide useful information with re-
spect to the radiographic prognosis of patients with knee
OA, in combination with other known risk factors. In the con-
text of future clinical development program for new SMOAD
medicines, the CTX-II proﬁle may be useful to judge the
likelihood of long-term radiological progression and hence
might help accelerate SMOAD development. Further evalu-
ation of the utility of CTX-II and other biochemical markers
of turnover of the joint tissues for clinical studies of potential
SMOADs is recommended.Conﬂict of interest
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